Immunosuppressants drugs - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.75 [0.62, 0.90]< 113%18 studies (18/-)99.9 %some concernlow moderatecrucial-
death or transfer to ICU 0.97 [0.50, 1.88]< 10%1 study (1/-)53.6 %lownot evaluable highcrucial-
deaths 0.80 [0.71, 0.89]< 18%28 studies (28/-)100.0 %some concernlow moderatecrucial-
deaths (time to event analysis only) 0.77 [0.59, 1.01]< 145%6 studies (6/-)97.2 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.69 [0.49, 0.96]< 163%9 studies (9/-)98.5 %some concernserious moderateimportant-
clinical improvement 1.20 [1.08, 1.33]> 112%8 studies (8/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.30 [1.03, 1.64]> 10%1 study (1/-)98.6 %lownot evaluable highimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.14 [1.03, 1.27]> 10%4 studies (4/-)99.4 %some concernnot evaluable moderateimportant-
death or ventilation 0.81 [0.72, 0.91]< 116%10 studies (10/-)100.0 %some concernlow moderateimportant-
hospital discharge 1.05 [0.88, 1.25]> 113%2 studies (2/-)70.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.70 [0.54, 0.90]< 10%6 studies (6/-)99.7 %some concernnot evaluable moderateimportant-
ICU admission 0.85 [0.49, 1.49]< 157%3 studies (3/-)71.2 %some concernnot evaluable moderatenon important-
recovery 0.64 [0.14, 2.92]> 10%1 study (1/-)28.3 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.94 [0.78, 1.13]< 10%10 studies (10/-)74.7 %some concerncritical moderateimportant-
superinfection 0.50 [0.32, 0.79]< 10%1 study (1/-)99.8 %lownot evaluable highimportant-
adverse events 1.37 [0.98, 1.93]< 157%7 studies (7/-)3.3 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.